StreetInsider.com News Articles

Form 8-K TuHURA Biosciences, Inc. For: May 26

Fri, 29 May 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260529/26576275.html

Form 8-K TuHURA Biosciences, Inc. For: May 26

Fri, 29 May 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260529/26576275.html

Form 4 TuHURA Biosciences, Inc. For: May 28 Filed by: Bianco James A.

Fri, 29 May 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260529/26575902.html

Form 4 TuHURA Biosciences, Inc. For: May 28 Filed by: Bianco James A.

Fri, 29 May 2026 16:37:00 -0400

si-local-file:///var/storage/secattach/20260529/26575902.html

Form 10-Q TuHURA Biosciences, Inc. For: Mar 31

Fri, 15 May 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260515/26507899.html

Form 10-Q TuHURA Biosciences, Inc. For: Mar 31

Fri, 15 May 2026 17:21:00 -0400

si-local-file:///var/storage/secattach/20260515/26507899.html

Form 8-K TuHURA Biosciences, Inc. For: May 15

Fri, 15 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260515/26507757.html

Form 8-K TuHURA Biosciences, Inc. For: May 15

Fri, 15 May 2026 17:11:00 -0400

si-local-file:///var/storage/secattach/20260515/26507757.html

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Fri, 15 May 2026 17:00:00 -0400

TAMPA, Fla., May 15, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ: HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today reported financial results for the Company's first quarter ended March 31, 2026, and provided a corporate update.

"I am very pleased with the progress we have made this past quarter as we continue to execute upon our corporate and development strategy. Importantly, we recently established a $50 million non-equity-based source of operating capital in the form of credit facility with our

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Fri, 15 May 2026 17:00:00 -0400

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Fri, 15 May 2026 17:00:00 -0400

TuHURA Biosciences Reports First Quarter 2026 Financial Results and Provides a Corporate Update

Fri, 15 May 2026 17:00:00 -0400

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Tue, 12 May 2026 07:30:00 -0400

TAMPA, Fla., May 12, 2026 /PRNewswire/ -- TuHURA Biosciences, Inc. (NASDAQ:HURA) ("TuHURA" or the "Company"), a Phase 3 immuno-oncology company developing novel therapeutics to overcome resistance to cancer immunotherapy, today announced James A. Bianco, M.D., President and Chief Executive Officer of TuHURA, will participate in a fireside chat, at the 4th Annual H.C. Wainwright BioConnect Investor Conference taking place in New York City.

4^th Annual H.C. Wainwright BioConnect Investor Conference
Date: Tuesday, May 19, 2026
Time: 2:00 pm ET
Links: To register and view presentation, click

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Tue, 12 May 2026 07:30:00 -0400

4^th Annual H.C. Wainwright BioConnect Investor Conference
Date: Tuesday, May 19, 2026
Time: 2:00 pm ET
Links: To register and view presentation, click

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Tue, 12 May 2026 07:30:00 -0400

4^th Annual H.C. Wainwright BioConnect Investor Conference
Date: Tuesday, May 19, 2026
Time: 2:00 pm ET
Links: To register and view presentation, click

TuHURA Biosciences to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

Tue, 12 May 2026 07:30:00 -0400

4^th Annual H.C. Wainwright BioConnect Investor Conference
Date: Tuesday, May 19, 2026
Time: 2:00 pm ET
Links: To register and view presentation, click

Form 8-K/A TuHURA Biosciences, Inc. For: Apr 02

Thu, 30 Apr 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260430/26409405.html

Form 8-K/A TuHURA Biosciences, Inc. For: Apr 02

Thu, 30 Apr 2026 16:45:00 -0400

si-local-file:///var/storage/secattach/20260430/26409405.html

Form 10-K/A TuHURA Biosciences, Inc. For: Dec 31

Thu, 30 Apr 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260430/26408968.html

Form 10-K/A TuHURA Biosciences, Inc. For: Dec 31

Thu, 30 Apr 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260430/26408968.html

Citizens Starts TuHURA Biosciences (HURA) at Market Outperform

Mon, 27 Apr 2026 01:58:44 -0400

Citizens analyst Silvan Turkcan initiates coverage on TuHURA Biosciences (NASDAQ: HURA) with a Market Outperform rating and a price target of $9.00.

The analyst comments: "We initiate coverage of TuHURA Biosciences, Inc. (HURA) with a Market Outperform rating and DCF-derived $9 price target. HURA is a clinical stage immuno-oncology company focused on novel mechanisms in cancer. TuHURA emerged out of the Morphogenesis (IFx-2.0) and subsequent Kineta (VISTA mAb) acquisitions and is led by industry veteran James Bianco. The company leverages new biological insights to target a new myeloid checkpoint and potentially build a new ADC class (Delta Opioid Receptor payload) to

Citizens Starts TuHURA Biosciences (HURA) at Market Outperform

Mon, 27 Apr 2026 01:58:44 -0400

Citizens analyst Silvan Turkcan initiates coverage on TuHURA Biosciences (NASDAQ: HURA) with a Market Outperform rating and a price target of $9.00.

Form 8-K TuHURA Biosciences, Inc. For: Apr 21

Wed, 22 Apr 2026 07:40:00 -0400

si-local-file:///var/storage/secattach/20260422/26347341.html

Form 8-K TuHURA Biosciences, Inc. For: Apr 21

Wed, 22 Apr 2026 07:40:00 -0400

si-local-file:///var/storage/secattach/20260422/26347341.html

TuHURA secures $50 million credit facility from major shareholder

Wed, 22 Apr 2026 07:30:39 -0400

TuHURA Biosciences Inc. (NASDAQ: HURA) announced it has secured a $50 million credit facility from an affiliate of its largest stockholder, K&V Investment One LLC, to fund clinical trials and operations.

The loan agreement allows the immuno-oncology company to draw funds monthly as needed for clinical development and operations. The facility carries a 12% annual interest rate with monthly interest payments and principal due at maturity on April 21, 2031. The loan is secured by company and subsidiary assets.

In connection with the credit facility, TuHURA granted the lender a low to mid-single digit percentage royalty on annual commercial sales of products